# HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCC

> **NCT05493332** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University** · enrollment: 93 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **PROCEDURE:** HAIC(FOLFOX)
- **DRUG:** Oxaliplatin
- **DRUG:** Leucovorin
- **DRUG:** Fluorouracil
- **DRUG:** Toripalimab
- **DRUG:** Donafenib

## Key facts

- **NCT ID:** NCT05493332
- **Lead sponsor:** Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09
- **Primary completion:** 2023-09
- **Final completion:** 2024-09
- **Target enrollment:** 93 (ESTIMATED)
- **Last updated:** 2022-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05493332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05493332, "HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCC". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT05493332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*